aTyr Pharma, Inc. is a biotechnology company focused on developing innovative therapies to address rare diseases by leveraging its proprietary expertise in the biology of tRNA synthetases. The company specializes in advancing treatments that modulate the immune system, with a keen interest in conditions such as neurodegenerative diseases and muscle wasting disorders. aTyr employs a unique platform that seeks to harness the natural functions of these proteins, aiming to deliver potential solutions that improve patients' quality of life and address unmet medical needs. Through rigorous research and clinical development processes, aTyr Pharma strives to bring transformative therapies to market. Read More
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK - October 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (NASDAQ: ATYR) of a class action securities lawsuit.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company’s possible violations of federal securities laws.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ATyr To Contact Him Directly To Discuss Their Options
The Law Offices of Frank R. Cruz announces an investigation of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company’s stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In aTyr (ATYR) To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). aTyr is a clinical stage biotechnology company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
